Coronary artery disease (CAD) and atrial fibrillation (AF) and frequently coexist, with overlapping cardiovascular risk factors [1]. Oral anticoagulants (OACs) are indicated for AF-related stroke prevention, while single antiplatelet therapy (SAPT) is standard for secondary prevention in stable CAD, recently renamed chronic coronary syndrome (CCS) [2–4]. Long-term OAC may also be indicated for other reasons than AF in CAD patients. The optimal long-term antithrombotic regimen in these patients remains debated.
